da1c4d8d-b07a-4aa1-8360-1c140ca16327
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74.8418891170431
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.420
- MTORC1_SIGNALING+0.420
- CHOLESTEROL_HOMEOSTASIS+0.410
- P53_PATHWAY+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.370
- PANCREAS_BETA_CELLS+0.350
- TNFA_SIGNALING_VIA_NFKB+0.350
- ESTROGEN_RESPONSE_LATE+0.330
- XENOBIOTIC_METABOLISM+0.320
- FATTY_ACID_METABOLISM+0.310
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.370
- INTERFERON_GAMMA_RESPONSE-0.320
- INTERFERON_ALPHA_RESPONSE-0.280
- E2F_TARGETS-0.240
- MYOGENESIS-0.140
- MITOTIC_SPINDLE-0.120
- G2M_CHECKPOINT-0.090
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.080
- HEDGEHOG_SIGNALING-0.080
- INFLAMMATORY_RESPONSE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-IQ-7632-01A-11R-2081-07 | — | — | 0.872 |
| 2 | SRR6013485 | — | cohortA4 | 0.817 |
| 3 | f34c57ee-92a6-4e3b-acde-7fd631c42f87 | — | — | 0.799 |
| 4 | bf93be3e-d4f1-4efb-9841-ca8ad81b237e | — | — | 0.774 |
| 5 | SRR2932820 | — | — | 0.767 |
| 6 | AUR-AD9F-TTM1-A-1-1-R-A542-39 | — | C | 0.761 |
| 7 | GSM5359444 | — | — | 0.745 |
| 8 | e94b6daf-3aed-4496-b64b-1b1a7d8e2011 | — | — | 0.744 |
| 9 | AUR-AD9F-TTM3-A-1-1-R-A542-39 | — | C | 0.742 |
| 10 | SRR1313101 | — | A | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.380 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |